| Claudia Ambrus, CRNA | |
|
199 Reedsdale Rd, Milton, MA 02186-3926 | |
| (617) 667-3364 | |
| (617) 667-5013 |
| Full Name | Claudia Ambrus |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 40 Years |
| Location | 199 Reedsdale Rd, Milton, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811962905 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 138775 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Beth Israel Deaconess Hospital - Milton | Milton, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Associated Physicians Of Harvard Medical Faculty Physicians At Beth Is | 6305749987 | 440 |
News Archive
Research led by the Centenary Institute, the University of Technology Sydney and the University of Queensland has shown for the first time a link between chronic obstructive pulmonary disease (COPD), an often fatal lung condition, and the gut microbiome.
Microfluidics International Corporation, today reported unaudited financial results for the first quarter ended March 31, 2010.
bitop AG, which specializes in the development and marketing of Ectoin-containing medical devices, announces that Ectoin significantly reduces nanoparticle-induced inflammatory reaction in rat lungs, one of the animal models for chronic obstructive pulmonary disease. It is the first time that Ectoin has been shown to have such an effect on nanoparticle-induced lung inflammation.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that on December 24, 2014 it closed its previously announced registered public offering.
Pharmalink AB, a specialty pharma company focused on orphan and niche products, has had core patents for its late-stage clinical candidate Nefecon® issued in the key markets United States, Europe, China and Hong Kong. A patent is pending in Japan.
› Verified 3 days ago
| Entity Name | Anaesthesia Associates Of Massachusetts, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568415289 PECOS PAC ID: 5193611267 Enrollment ID: O20040225000842 |
News Archive
Research led by the Centenary Institute, the University of Technology Sydney and the University of Queensland has shown for the first time a link between chronic obstructive pulmonary disease (COPD), an often fatal lung condition, and the gut microbiome.
Microfluidics International Corporation, today reported unaudited financial results for the first quarter ended March 31, 2010.
bitop AG, which specializes in the development and marketing of Ectoin-containing medical devices, announces that Ectoin significantly reduces nanoparticle-induced inflammatory reaction in rat lungs, one of the animal models for chronic obstructive pulmonary disease. It is the first time that Ectoin has been shown to have such an effect on nanoparticle-induced lung inflammation.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that on December 24, 2014 it closed its previously announced registered public offering.
Pharmalink AB, a specialty pharma company focused on orphan and niche products, has had core patents for its late-stage clinical candidate Nefecon® issued in the key markets United States, Europe, China and Hong Kong. A patent is pending in Japan.
› Verified 3 days ago
| Entity Name | Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093756629 PECOS PAC ID: 4486567104 Enrollment ID: O20040315000395 |
News Archive
Research led by the Centenary Institute, the University of Technology Sydney and the University of Queensland has shown for the first time a link between chronic obstructive pulmonary disease (COPD), an often fatal lung condition, and the gut microbiome.
Microfluidics International Corporation, today reported unaudited financial results for the first quarter ended March 31, 2010.
bitop AG, which specializes in the development and marketing of Ectoin-containing medical devices, announces that Ectoin significantly reduces nanoparticle-induced inflammatory reaction in rat lungs, one of the animal models for chronic obstructive pulmonary disease. It is the first time that Ectoin has been shown to have such an effect on nanoparticle-induced lung inflammation.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that on December 24, 2014 it closed its previously announced registered public offering.
Pharmalink AB, a specialty pharma company focused on orphan and niche products, has had core patents for its late-stage clinical candidate Nefecon® issued in the key markets United States, Europe, China and Hong Kong. A patent is pending in Japan.
› Verified 3 days ago
| Entity Name | Associated Physicians Of Harvard Medical Faculty Physicians At Beth Is |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1245773308 PECOS PAC ID: 6305749987 Enrollment ID: O20170628003015 |
News Archive
Research led by the Centenary Institute, the University of Technology Sydney and the University of Queensland has shown for the first time a link between chronic obstructive pulmonary disease (COPD), an often fatal lung condition, and the gut microbiome.
Microfluidics International Corporation, today reported unaudited financial results for the first quarter ended March 31, 2010.
bitop AG, which specializes in the development and marketing of Ectoin-containing medical devices, announces that Ectoin significantly reduces nanoparticle-induced inflammatory reaction in rat lungs, one of the animal models for chronic obstructive pulmonary disease. It is the first time that Ectoin has been shown to have such an effect on nanoparticle-induced lung inflammation.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that on December 24, 2014 it closed its previously announced registered public offering.
Pharmalink AB, a specialty pharma company focused on orphan and niche products, has had core patents for its late-stage clinical candidate Nefecon® issued in the key markets United States, Europe, China and Hong Kong. A patent is pending in Japan.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Claudia Ambrus, CRNA 199 Reedsdale Rd, Milton, MA 02186-3926 Ph: (617) 667-3364 | Claudia Ambrus, CRNA 199 Reedsdale Rd, Milton, MA 02186-3926 Ph: (617) 667-3364 |
News Archive
Research led by the Centenary Institute, the University of Technology Sydney and the University of Queensland has shown for the first time a link between chronic obstructive pulmonary disease (COPD), an often fatal lung condition, and the gut microbiome.
Microfluidics International Corporation, today reported unaudited financial results for the first quarter ended March 31, 2010.
bitop AG, which specializes in the development and marketing of Ectoin-containing medical devices, announces that Ectoin significantly reduces nanoparticle-induced inflammatory reaction in rat lungs, one of the animal models for chronic obstructive pulmonary disease. It is the first time that Ectoin has been shown to have such an effect on nanoparticle-induced lung inflammation.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that on December 24, 2014 it closed its previously announced registered public offering.
Pharmalink AB, a specialty pharma company focused on orphan and niche products, has had core patents for its late-stage clinical candidate Nefecon® issued in the key markets United States, Europe, China and Hong Kong. A patent is pending in Japan.
› Verified 3 days ago
Lori A Cetrino, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 199 Reedsdale Rd, Milton, MA 02186 Phone: 617-667-3364 Fax: 617-667-5013 | |
Joan M Botelho, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 199 Reedsdale Rd, Milton, MA 02186 Phone: 617-667-3364 Fax: 617-664-5013 | |
Erin Herrmann, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 199 Reedsdale Rd, Milton, MA 02186 Phone: 617-667-3364 | |
Mrs. Patricia Ann Severance, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 92 Highland St, Milton, MA 02186 Phone: 617-313-1172 | |
Mr. Daniel J Marriggi, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 92 Highland St, Milton, MA 02186 Phone: 617-313-1172 | |
Tony Tang, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 199 Reedsdale Rd, Milton, MA 02186 Phone: 617-696-4600 |